O'Kelly Noel, Robertson William, Smith Jude, Dexter Jonathan, Carroll-Hawkins Collette, Ghosh Sudip
Noel O'Kelly, Community Health Services, Leicestershire Partnership Trust, Melton, Leicestershire, Le13 1SJ, United Kingdom.
World J Cardiol. 2012 Mar 26;4(3):66-71. doi: 10.4330/wjc.v4.i3.66.
To establish the short term outcomes of heart failure (HF) patients in the community who have concurrent chronic obstructive pulmonary disease (COPD).
We evaluated 783 patients (27.2%) with left ventricular systolic dysfunction under the care of a regional nurse-led community HF team between June 2007 and June 2010 through a database analysis.
One hundred and one patients (12.9%) also had a diagnosis of COPD; 94% of patients were treated with loop diuretics, 83% with angiotensin converting enzyme inhibitors, 74% with β-blockers; 10.6% with bronchodilators; and 42% with aldosterone antagonists. The mean age of the patients was 77.9 ± 5.7 years; 43% were female and mean New York Heart Association class was 2.3 ± 0.6. The mean follow-up was 28.2 ± 2.9 mo. β-blocker utilization was markedly lower in patients receiving bronchodilators compared with those not taking bronchodilators (overall 21.7% vs 81%, P < 0.001). The 24-mo survival was 93% in patients with HF alone and 89% in those with both comorbidities (P = not significant). The presence of COPD was associated with increased risk of HF hospitalization [hazard ratio (HR): 1.56; 95% CI: 1.4-2.1; P < 0.001] and major adverse cardiovascular events (HR: 1.23; 95% CI: 1.03-1.75; P < 0.001).
COPD is a common comorbidity in ambulatory HF patients in the community and is a powerful predictor of worsening HF. It does not however appear to affect short-term mortality in ambulatory HF patients.
确定社区中合并慢性阻塞性肺疾病(COPD)的心力衰竭(HF)患者的短期预后。
通过数据库分析,我们评估了2007年6月至2010年6月间由地区护士主导的社区HF团队护理的783例左心室收缩功能障碍患者(占27.2%)。
101例患者(占12.9%)同时被诊断患有COPD;94%的患者接受袢利尿剂治疗,83%接受血管紧张素转换酶抑制剂治疗,74%接受β受体阻滞剂治疗;10.6%接受支气管扩张剂治疗;42%接受醛固酮拮抗剂治疗。患者的平均年龄为77.9±5.7岁;43%为女性,纽约心脏协会平均分级为2.3±0.6。平均随访时间为28.2±2.9个月。与未服用支气管扩张剂的患者相比,服用支气管扩张剂的患者β受体阻滞剂的使用率明显较低(总体分别为21.7%和81%,P<0.001)。单纯HF患者的24个月生存率为93%,合并两种疾病的患者为89%(P无统计学意义)。COPD的存在与HF住院风险增加相关[风险比(HR):1.56;95%置信区间(CI):1.4 - 2.1;P<0.001]以及主要不良心血管事件(HR:1.23;95%CI:1.03 - 1.75;P<0.001)。
COPD是社区门诊HF患者常见的合并症,是HF病情恶化的有力预测指标。然而,它似乎并不影响门诊HF患者的短期死亡率。